Alaa Halawa
Independent DirectorMr. Alaa Halawa, M.B.A., serves as Head of Healthcare of Mubadala Capital LLC since October 2024. He joined the firm in 2009. At Mubadala Capital LLC, he also served as Executive Director, Partner & Co-Head of US Ventures until October 2024. He serves as Member of the Industry Advisory Board of Flare Capital Partners, was Director of Alloy Therapeutics, Inc until June 2026. (where he was previously Board Observer since March 2021), as Independent Director of Neumora Therapeutics, Inc. since September 2022. He is a Director of Ollin Biosciences, Inc. He is a Director of Pretzel Therapeutics, Inc., as a board member of Innovaccer and as Board Observer at Outpace Bio since January 2021. Previously, he served as a director at GlobalFoundries from January 2014 until February 2015. Mr. Halawa oversees Mubadala Capital's healthcare investment strategy across Ventures, Growth and Private Equity in life sciences, healthcare technology and healthcare services. He focuses on Healthcare and has led investments in a number of pioneering companies, including Recursion, Neumora Therapeutics, Exscientia and Vir Biotechnology. He was part of the early team that helped build GlobalFoundries and played a key role in its transformation into a publicly traded company. He holds an M.B.A. in Management from Cornell University from 2014 to 2016 and a B.S. in Electrical Engineering from the University of Jordan from 1999 to 2004.
Positions
- Company NameNeumora Therapeutics, Inc.Stock CodeNMRAPositionIndependent DirectorColleagues
- PLPaul L. BernsExecutive Chairman
- JPJoshua PintoPresident, CEO & Director
- DSDaljit Singh AuroraChief Operationg & Development officer
- MLMichael Lee MilliganCFO & Principal Accounting Officer
- NBNicholas BrandonChief Scientific Officer
- MKMatthew K. FustIndependent Director
- KMKristina M. BurowIndependent Director
